Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC lands $16 million judgment against supplement firms

This article was originally published in The Tan Sheet

Executive Summary

The U.S. District Court for the Northern District of Georgia has issued a final monetary judgment and permanent prohibitions against the marketers of dietary supplement products Thermalean and Lipodrene for weight loss and Spontane-ES for erectile dysfunction. Defendants National Urological Group, Hi-Tech Pharmaceuticals and several others are found liable for $15.8 million in deceptive sales based on claims that their products caused 19 percent loss in total body weight and were clinically proven to treat 90 percent of men with ED, the Federal Trade Commission says Jan. 15. The marketers also are barred from making such claims in the absence of scientific evidence. The court granted FTC's motion for summary judgment in June, after the defendants unsuccessfully argued that the "non-actionable puffery" in their ads granted them protection under the FTC Act (1"The Tan Sheet" June 16, 2008, p. 8)

You may also be interested in...

Ruling Against Hi-Tech Pharmaceuticals Spotlights FTC Strategies

A recent court ruling emphasizes Federal Trade Commission strategies to prevent companies from repeatedly making false claims, stretching substantiation data, using deceptive endorsements and creating shell businesses

'Sakigake' Treatment Gives Enhertu Rapid Japan OK For Gastric Cancer

Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.

Finance Watch: Five More Biopharma IPOs In The US Raise $624.7m

Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts